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Abstract
(Z)-3-(1H -imidazol-1-yl)-2-phenylpropenenitrile (imppn) reacts with Cu(ClO4)2 /6H2O, Zn(CH3CO2)2 /2H2O and AgClO4
producing [Cu(imppn)4](ClO4)2 /H2O (1), [Zn(imppn)2(CH3CO2)2] /2H2O (2) and [Ag2(imppn)4(ClO4)2] (3), respectively. Complexes
2 and 3 were characterised by X-ray crystallography. In 2 the metal lies in a pseudo-tetrahedral environment and is ligated by the
imine nitrogens of two imppn ligands and an oxygen atom from each of two monodentate acetate anions. In the dimeric Ag(I)
complex 3 each metal is coordinated to the imine nitrogens of two imppn ligands in an almost linear fashion and the two
[Ag(imppn)2]
 units are linked by an Ag/Ag bond, supported by two trans bridging bidentate perchlorate groups and by p/p
interactions between the ligands. In vitro tests on the ability of the compounds to inhibit the growth of the pathogenic yeast Candida
albicans showed that imppn and its metal complexes were markedly less effective than the prescription drug, ketoconazole.
# 2003 Elsevier Science Ltd. All rights reserved.
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1. Introduction
Azole drugs, such as ketoconazole and fluconazole
(Fig. 1), are currently prescribed to treat fungal infec-
tions such as those caused by the pathogenic yeast
Candida albicans .
It is generally accepted [1/3] that the fungicidal
activity of these N -substituted imidazole and triazole
derivatives is derived, at least partly, from their ability
to inhibit ergosterol biosynthesis in fungi and yeast cells.
The inhibition leads to diminished levels of sterol in the
fungal cell membrane as well as an accumulation of
toxic ergosterol intermediates which may play a key role
in the killing of the fungal cell [4]. Resistance to azole
drugs has been seen clinically [5] and is mediated by a
combination of factors including alterations in the
ergosterol biosynthetic pathway, increased expression
of drug efflux pumps and, possibly, degradation of the
drug before it exerts an effect [6].
Lanosterol is an obligatory precursor to ergosterol
and the initial step of lanosterol metabolism is the
removal of its 14a-methyl group [7], a reaction catalyzed
by a cytochrome P-450-containing monooxygenase
system present in the microsomes. The interaction of
the azoles with the cytochrome results in a depletion of
ergosterol and coincides with an accumulation of
lanosterol and some other 14a-methylsterols in the cells.
The decreased availability of ergosterol, together with
the accumulation of 14a-methylsterols, greatly disturbs
the permeability of cell membranes, the activity of
membrane-bound enzymes and ultimately curbs cell
growth. The azoles interact with the cytochrome at
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two sites. One is the sixth coordination site of the heme
Fe(III) in the protoporphyrin moiety of the cytochrome
and the other is some region of the apoprotein near the
heme. Azole structure/activity relationship studies sug-
gest that the binding regions of the apoprotein for these
fungicides must be located over the sixth coordination
site of the heme. O2 required for the demethylation
process is activated at the sixth coordination position of
the heme and the lanosterol-binding site must locate
over the O2 activating site. Thus, azole fungicides must
occupy both the substrate-binding (major role) and the
O2-activating sites (minor role) of the P-450 simulta-
neously, and therefore, strongly inhibit the catalytic
activity of the cytochrome. Of great importance is the
fact that the P-450 of fungal microsomes is much more
sensitive to azole drugs than that of mammalian
microsomes, thus, ensuring selective toxicity to fungal
cells.
As part of our ongoing efforts into finding new and
efficient metal-based anti-fungal drugs [8/15] we have
prepared Cu(II), Zn(II) and Ag(I) complexes of the
imidazole derivative, (Z)-3-(1H-imidazol-1-yl)-2-phenyl-
propenenitrile (imppn) (Fig. 2) [16], and structurally
characterised the latter two. The in vivo anti-Candida
activity of metal-free imppn and its metal complexes was
also investigated.
2. Results and discussion
Treating imppn with simple Cu(II), Zn(II) and Ag(I)
salts gave [Cu(imppn)4](ClO4)2 /H2O (1), [Zn(imppn)2-
(CH3CO2)2] /2H2O (2) and [Ag2(imppn)4(ClO4)2] (3) in
good yield. The related complexes, [Cu(imppn)2Cl2] and
[Zn(imppnCl)2Cl2] {imppnCl/(Z)-3-(1H-imidazol-1-
yl)-2-(2-chlorophenylpropenenitrile)} were previously
prepared using CuCl2 and ZnCl2, respectively [16].
The X-ray crystal structure of the Zn(II) complex 2 is
shown in Fig. 3 and important bond lengths and angles
are given in Table 1. The metal lies in a pseudo-
tetrahedral environment and is ligated by the imine
nitrogens of two imppn ligands and an oxygen atom
from each of two monodentate acetate anions. A water
molecule is hydrogen-bonded to the uncoordinated
oxygen of each acetate. The imppn ligand shown on
the left of the metal in Fig. 3 is disordered 50:50 between
two sites, sharing two carbon positions. The complex
molecules are linked by hydrogen-bonding via the water
molecules and the ligand labeled ‘A’ shows extensive p/
p stacking in the unit cell (Fig. 4).
In the dimeric Ag(I) complex 3 (Fig. 4 and Table 2)
each metal is coordinated to the imine nitrogens of two
imppn ligands in an almost linear fashion {N(1A)/Ag/
N(1B)/174.61(14)8}. The two [Ag(imppn)2]
 units are
linked by an Ag/Ag bond, supported by two trans
bridging bidentate perchlorate groups (Ag/O 2.822(4)
and 3.094(4) A˚) and by p/p interactions (Fig. 5)
between the ligands (interplanar separation approxi-
mately 3.6 A˚). The Ag/O perchlorate distances in 3
(2.822(4) and 3.094(4) A˚) are comparable to those found
in the disilver(I) cryptate [Ag2(imBT)](ClO4)2 [17], where
the perchlorate anions link the disilver cations in zig-zag
perchlorate-bridged chains (Ag/O interactions range
from 2.681(6) to 3.335 A˚). Although the formal closed-
shell d10 character of Ag(I) would appear to rule out any
intermetallic Ag/Ag bonding in silver(I) complexes
there are many examples where small but definite
attractive forces (argentophilic interactions) between
the metal cations do occur [18]. The relatively large
Ag/Ag distance in 3 (3.3357 A˚) is comparable to those
found in the related hexanuclear complex [Ag(imidazo-
le)2]6(ClO4)6, where the unbridged structure had an Ag/
Ag distance of 3.49 A˚ in the central Ag3 triangle and
3.05 A˚ in the peripheral Ag2 moieties [19]. Although
there are no obvious inter-dimer interactions in 3
involving the silver atoms there are some p/p interac-
tions running through the lattice (Figs. 6 and 7).
The results of the anti-Candida tests of metal-free
imppn, simple metal salts and imppn metal complexes
are given in Table 3. The tests were conducted in a
water-based culture medium and data for the prescrip-
tion anti-fungal drug ketoconazole and for a control
experiment (no added drug) are also tabulated. On
comparing the water-insoluble metal-free azoles, imppn
and ketoconazole, the latter is seen to be a much more
potent drug in its action on Candida cells, suggesting
that there is little or no interaction between imppn and
cytochrome P-450. Furthermore, coordination of imppn
to produce water-insoluble Cu(II), Zn(II) and Ag(I)
complexes did not enhance the antimicrobial activity.
Fig. 1. Ketoconazole and fluconazole.
Fig. 2. (Z)-3-(1H -imidazol-1-yl)-2-phenylpropenenitrile (imppn).
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These complexes were also insoluble in the test media. In
contrast, the simple water-soluble metal salts, AgClO4,
Cu(ClO4)2 /6H2O and, to a lesser extent Zn(CH3CO2)2 /
2H2O, were much superior in their ability to inhibit
fungal cell growth than their respective imppn com-
plexes, with AgClO4 being the most effective of all of the
test drugs down to a concentration of 10 mg cm3. At
lower drug concentrations ketoconazole exerts the
greatest inhibitory effect.
Fig. 3. Structure of [Zn(imppn)2(CH3CO2)2] /2H2O (2).
Table 1
Selected bond lengths (A˚) and angles (8) for complex 2
Bond lengths
Zn/O(21) 1.9714(18)
Zn/O(31) 1.972(2)
Zn/N(1A) 2.012(2)
Zn/N(1B) 2.020(2)
Bond angles
O(21)/Zn/O(31) 94.99(8)
O(21)/Zn/N(1A) 108.73(8)
O(31)/Zn/N(1A) 115.40(9)
O(21)/Zn/N(1B) 113.97(8)
O(31)/Zn/N(1B) 110.97(9)
N(1A)/Zn/N(1B) 111.80(9)
Fig. 4. p/p stacking in the unit cell of (2).
Table 2
Selected bond lengths (A˚) and angles (8) for complex 3
Bond lengths
Ag/N(1A) 2.115(4)
Ag/N(1B) 2.117(4)
Ag/Ag#1 3.3357(9)
Ag/O(14)#1 2.822(4)
Ag/O(12) 3.094(4)
Bond angles
N(1A)/Ag/N(1B) 174.61(14)
N(1A)/Ag/O(14)#1 97.27(12)
N(1B)/Ag/O(14)#1 83.78(13)
N(1A)/Ag/O(12) 77.06(12)
N(1B)/Ag/O(12) 103.92(12)
O(14)#1/Ag/O(12) 157.57(10)
Symmetry transformations used to generate equivalent atoms: #1
/x/1, /y/1, /z/1.
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It is unlikely that the stark difference in the anti-
fungal activity of AgClO4 and [Ag2(imppn)4(ClO4)2] (3)
can be explained solely in terms of inequalities in water-
solubility. The antimicrobial effects of silver metal and
silver complexes is well established [20/22] and there are
contrasting effects regarding drug solubility. For exam-
ple, the water-insoluble, polymeric complex sulphadia-
zinesilver(I) (commercially known as silvadene and
flamazine) [23] is administered topically as an antibac-
terial and antifungal agent to treat burn wounds. The
antimicrobial activity of sulphadiazinesilver(I) has been
ascribed to the slow release of Ag ions at the site of the
wound. Aqueous solutions of silver nitrate and water/
DMSO solutions of sulphadiazinesilver(I) and other
silver(I) complexes irreversibly deactivate isolated phos-
phomannose isomerase (PMI), a zinc metalloenzyme
importance in cell wall biosynthesis in C. albicans . [24].
The thiol functional group of an accessible surface
cysteine Cys-150 residue of C. albicans PMI was
confirmed as the site of action of the silver complex,
and the drug also inactivates human PMI. In addition,
electron microscopy studies on C. utilis revealed that
sorption of Ag ions from solution was accompanied
by the formation of silver-containing granules, either
bound to cells or located among them [25]. It is also
known that the toxicity of Ag in an aqueous environ-
ment depends on the concentration of active, free Ag
ion and that decreasing the availability of the free metal
ion by complexing ligands (thiosulphate or chloride)
curtails the inhibitory effects on microorganisms [26].
Cyclic voltammetry data for acetonitrile solutions of
the simple Ag(I) salts, AgClO4, AgNO3 and
AgCH3CO2, and also the imppn complex 3 are given
in Table 4. Potentials are quoted with respect to the
saturated calomel electrode (SCE). An acetonitrile
solution of metal-free imppn was electroinactive in the
potential range/1000 to/1000 mV. All of the samples
containing Ag ion showed a single, irreversible catho-
dic wave (Ec) for the reduction process Ag
0/Ag0. In
addition to the cathodic wave each voltammogram also
contained a large anodic stripping peak (Ea) for the
reoxidation of the plated silver metal (Ag00/Ag). Not
surprisingly, more negative potentials were required to
reduce the metal ion (Ag0/Ag0) in complexes contain-
ing the better complexing ligands CH3CO2
 and imppn,
compared to those with just ClO4
 and NO3
. It is
expected that AgClO4 and AgNO3 would completely
ionize in acetonitrile and exist as the solvated cation
[Ag(CH3CN)n ]
.
In conclusion, the derivatised imidazole imppn readily
coordinates to transition metal ions through its imine N-
atom, and in the case of Ag(I) a dimeric complex forms
Fig. 5. Structure of [Ag2(imppn)4(ClO4)2] (3).
Fig. 6. p/p interactions within the dimer molecule 3.
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containing an Ag/Ag bond. Imppn and its metal
complexes are markedly less effective than the prescrip-
tion drug ketoconazole at preventing the growth of C.
albicans , in vitro. AgClO4, Cu(ClO4)2 /6H2O and, to a
lesser extent Zn(CH3CO2)2 /2H2O, were much better at
inhibiting fungal cell growth than their respective imppn
complexes.
3. Experimental
Chemicals were purchased from commercial sources
and, unless specified, were used without further purifi-
cation. The preparation of imppn and related com-
pounds will be published elsewhere. Cyclic voltammetry
experiments were preformed using a low noise potentio-
stat (Biostat II, Electrochemical and Medical systems,
Newbury, UK) and data acquisition was carried out
using a Gateway GP6-350 computer, a Powerlab/400
interface system (AD Instruments Ltd, East Sussex,
UK) and Echem for Windows software (AD Instru-
ments Ltd). The Pt disk working electrode (5-cm length)
was made from Teflon-insulated platinum/iridium (90%/
10%) wire (125-mm bare diameter, 160-mm coated
diameter (5 T) obtained from Advent Research Materi-
als, Suffolk, UK). A silver wire and a SCE were used as
Fig. 7. p/p stacking in the unit cell of 3.
Table 3
Anti-Candida activity (expressed as % growth of fungal cells)
Drug concentration (mg cm3)
100 (%) 50 (%) 20 (%) 10 (%) 5 (%) 2.5 (%) 1.25 (%)
Control 100 100 100 100 100 100 100
Ketoconazole 5 7 14 20 23 25 54
AgClO4 1 2 2 3 79 100 100
Cu(ClO4)2 /6H2O 6 6 71 93 94 100 100
Zn(CH3CO2)2 /2H2O 48 74 94 100 100 100 100
imppn 73 88 90 95 95 96 100
[Cu(imppn)4](ClO4)2 /H2O (1) 85 90 97 100 100 100 100
[Zn(imppn)2(CH3CO2)2] /2H2O (2) 74 83 100 100 100 100 100
[Ag2(imppn)4(ClO4)2] (3) 75 95 100 100 100 100 100
Table 4
Cyclic voltammetry data a
Ec (mV) Ea (mV)
AgClO4 /152 /288
AgNO3 /134 /310
AgCH3CO2 /25 /282
[Ag2(imppn)4(ClO4)2] (3) /92 /322
a Potentials are quoted with respect to the SCE.
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the auxiliary and reference electrodes, respectively.
Fresh solutions (1 mmol) of the complexes were made
up in the supporting electrolyte solution (0.1 mol dm3
solution of tetraethylammonium perchlorate in dry,
purified acetonitrile). The complex solutions were dea-
erated with O2-free N2 for 20 min prior to each
experiment and cycles were run at a scan rate of 100
mV s1. Infrared spectra of solids (in a KBr matrix)
were recorded in the region 4000/400 cm1 on a
Nicolet FT/IR Impact 400D infrared spectrometer.
1H NMR spectra were run on a Bruker Avance 300
MHz instrument. Solid state magnetic susceptibility
measurements were made at room temperature using a
Johnson Matthey Magnetic Susceptibility Balance and
[HgCo(SCN)4] was used as a reference standard. Micro-
analytical data were provided by the Microanalytical
Laboratory, National University of Ireland, Cork, Ire-
land.
3.1. [Cu(imppn)4](ClO4)2 /H2O (1)
Into a solution of Cu(ClO4)2 /6H2O (0.37 g, 1 mmol)
in ethanol (10 cm3) was added imppn (0.78 g, 4 mmol).
The light purple suspension was stirred for 1 h at room
temperature. The purple precipitate was filtered and
washed with small volumes of water, ethanol and ether
and then allowed to air dry. Yield 0.88 g (83%). The
complex was insoluble in water and all common organic
solvents. Anal. Found: C, 54.46; H, 3.42; N, 15.63. Calc:
C, 54.37; H, 3.42; N, 15.84%. IR: 3149, 2236, 1646,
1553, 1516, 1123, 627 cm1. meff: 2.15 BM.
3.2. [Zn(imppn)2(CH3CO2)2] /2H2O (2)
A mixture of Zn(CH3CO2)2.2H2O (0.27 g, 1.2 mmol)
and imppn (1 g, 5.1 mmol) in acetonitrile (10 cm3) was
refluxed for 3 h. On cooling the complex crystallised and
was then recrystallised from acetonitrile. Yield: 0.59 g
(80%). The complex was soluble when warmed in
acetonitrile, ethanol and methanol and was insoluble
in water. Anal. Found: C, 55.11; H, 4.57; N, 13.65.
Calc.: C, 55.14; H, 4.63; N, 13.78%. IR: 3432, 3124,
2224, 1670, 1603, 1510, 1406, 1233, 1116, 941, 689, 492
cm1. 1H NMR (ppm DMSO): 8.61 (s, 1H), 8.53 (s,
1H), 8.06 (s, 1H), 7.7 (m, 2H), 7.5 (m, 3H), 7.33 (s, 1H),
1.87 (s, 3H).
3.3. [Ag2(imppn)4(ClO4)2] (3)
Into a solution of AgClO4 (0.2 g, 1 mmol) in ethanol
(10 cm3) was added imppn (0.39 g, 2 mmol). The cream
coloured suspension was stirred for 1 h at room
temperature. The white solid product was filtered off,
washed with small volumes of water, ethanol and ether
and then allowed air dry. Yield: 0.51 g (85%). The
complex was soluble only in acetonitrile and was
recrystallised using this solvent. Anal. Found: C,
48.45; H, 3.06; N, 14.34. Calc.: C, 48.27; H, 3.04; N,
14.06%. IR: 3112, 2236, 1646, 1535, 1492, 1092, 633
cm1. 1H NMR (ppm DMSO): 8.45 (s, 1H), 8.33 (s,
1H), 7.9 (s, 1H), 7.6 (m, 2H), 7.4 (m, 3H), 7.2 (s, 1H).
3.4. X-ray crystallography
Crystal data for [Zn(imppn)2(CH3CO2)2] /2H2O (2)
and [Ag2(imppn)4(ClO4)2] (3) are summarized in Table
5. Data sets for both complexes were collected using a
Bruker SMART1000 diffractometer. Structure 2 data
was solved by Patterson methods and refined by full-
Table 5
Summary of crystal data, data collection, structure solution and
refinement details for complexes 2 and 3
2 3
Complex [Zn(imppn)2-
(CH3CO2)2] /2H2O
[Ag2(imppn)4-
(ClO4)2]
Empirical formula C28H28N6O6Zn C24H18AgClN6O4
Formula weight 609.93 1195.52
Temperature (K) 150(2) 150(2)
Wavelength (A˚) 0.71073 0.71073
Crystal system monoclinic triclinic
Space group P21/c P/1¯
Unit cell dimensions
a (A˚) 8.7381(6) 8.5902(19)
b (A˚) 44.059(3) 9.300(2)
c (A˚) 7.9784(5) 16.240(4)
a (8) 90 96.715(3)
b (8) 112.7320(10) 92.875(3)
g (8) 90 116.427(3)
Volume(A˚3) 2833.0(3) 1146.2(4)
Z 4 2
Dcalc (g cm
3) 1.430 1.732
Absorption coefficient
(mm1)
0.919 1.042
F (0 0 0) 1264 600
Crystal size (mm) 0.37/0.25/0.03 0.35/0.22/0.02
u Range (8) 2.53/28.62 2.48/25.00
Index ranges /115/h5/11,
/595/k5/58,
/105/l5/10
/105/h5/10,
/115/k5/11,
/195/l5/19
Reflections collected 21 784 8012
Independent reflections 6596 [Rint/
0.0427]
3984 [Rint/0.0383]
Completeness to theta (/28.628) 90.7% (/25.008) 98.7%
Absorption correction multiscan Multiscan
Max and min transmission 1.00000 and
0.451998
1.000000 and
0.817122
Refinement method full-matrix least-
squares on F2
full-matrix least-
squares on F2
Data/restraints/parameters 6596/0/435 3984/0/325
Goodness-of-fit on F2 1.137 1.031
Final R indices [I/2s (I )] R1/0.0504,
wR2/0.0972
R1/0.0407,
wR2/0.0891
R indices (all data) R1/0.0706,
wR2/0.1035
R1/0.0620,
wR2/0.0960
Largest diff. peak and hole
(e A˚3)
0.403 and /0.743 0.696 and /0.671
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matrix least-squares on F2 using all the data [27]. All the
non-hydrogen atoms were refined with anisotropic
atomic displacement factors and hydrogen atoms at-
tached to carbon were inserted at calculated positions.
The hydrogen atoms bonded to oxygen were located
from difference maps and not further refined. Structure
3 was solved by direct methods and refined by full-
matrix least-squares on F2 [27]. All non-hydrogen atoms
were refined with anisotropic atomic displacement
parameters and hydrogen atoms were inserted at
calculated positions.
3.5. Anti-Candida testing
C. albicans ATCC 10231 was obtained from the
American Type Culture Collection (Manasas, VA).
Culture conditions and measurement of drug minimum
inhibitory concentrations (MICs) were as previously
described [14,15]. Only AgClO4, Cu(ClO4)2 /6H2O and
Zn(CH3CO2)2 /2H2O were soluble in the aqueous test
media.
4. Supplementary material
Crystallographic data for the structural analysis have
been deposited with the Cambridge Crystallographic
Data Centre, CCDC Nos. 173759 and 173760 for the
compounds Ag(I) and Zn(II), respectively. Copies of
this information may be obtained free of charge from
the Director, CCDC, 12 Union Road, Cambridge CB2
1EZ, England (fax: /44-1223-336033; e-mail: deposit@
ccdc.cam.ac.uk or www: http://www.ccdc.cam.ac.uk).
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